2019Annual report
Message
From our Chair of the Board and Executive Director
2019 in numbers
23
new chemical entities in DNDi’s R&D pipeline
18
clinical trials at 59 sites in 20 countries
2,710
patients in active DNDi clinical studies
Responding to COVID-19
We can’t look back on our progress in 2019 without acknowledging the unprecedented challenges we face today. In the face of the global pandemic, our teams are working to accelerate research to protect the most vulnerable.
The urgency of innovation
The last decade has seen remarkable progress against neglected tropical diseases. What will it take to secure and sustain new gains in the decade to come? Bringing the best science for the most neglected is more important than ever.
Prioritizing paediatric R&D
We’ve developed four child-friendly treatments that have saved millions of lives. With new treatments in the R&D pipeline, we’re working to ensure more vulnerable children can benefit from the fruits of scientific progress.
Globally networked to conduct research where it's needed most
18 clinical studies for 6 diseases, at 59 sites in 20 countries
Sleeping sickness:
the last mile challenge
The development of fexinidazole – the first safe, effective, all-oral treatment for sleeping sickness – required tremendous cooperation and determination to enable world-class clinical research in some of the most remote African communities. Our African partners are now driving efforts to ensure widespread patient access to the game-changing drug for all patients in need.
Diseases & projects
No one should suffer from lack of treatment because their disease can’t turn a profit
New hope to stop a silent killer
Shorter, safer treatments are urgently needed for millions of people affected by Chagas disease. Current treatment is effective but lasts eight weeks and sometimes has serious side effects. Our study in Bolivia showed treatment could be reduced to just two weeks – and be just as effective.
2019 R&D highlights
We’ve built a robust portfolio of 46 R&D projects, including 23 entirely new compounds in testing – with several progressing to the next stage of development in 2019.
This progress would not be possible without the essential contributions of our global network of R&D partners.
2019 financial information
DNDi goes beyond the required audited financial statements in providing additional key financial performance indicators on expenditures and contributions.
A word of thanks
DNDi has now delivered eight new treatments for neglected patients and aims to deliver another eight to ten, for a total of 16-18 new treatments by 2023. We are deeply grateful for the support of all our donors and partners, and for their commitment and collaboration since 2003.
How your donations are used
All contributions large and small have helped advance DNDi’s mission and goals.
88%
Social mission: R&D, strengthening capacity, and advocacy
8%
General management
4%
Fundraising
Visit our website
Stay in touch
Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License